EX1
Pharmaceuticals, Biotechnology & Life Sciences
Exopharm
- Short interest
- 0.00%
- −0.01 pp 30d
- as of 12 Dec 2022
- Reported shorts
- 6.5K
- Shares on issue
- 157.212M
Exopharm (EX1) financials
Results, ratios and statements
Fundamentals
Our data providers hold no financial statements for EX1 (last checked 15 Oct 2026). The company's own filings are listed below.
Financial reports
The company's own filings, newest first
- Quarterly Activities Report and Appendix 4CQuarterly Report22 Jul 2026via asx_announcements
- Quarterly Activities Report and Appendix 4CQuarterly Report28 Apr 2026via asx_announcements
- Appendix 4D and Half Year Report for period 31 Dec 2025Half Year Results27 Feb 2026via asx_announcements
- Quarterly Activities Report and Appendix 4CQuarterly Report30 Jan 2026via asx_announcements
- September 2025 Quarterly Activities Report CorrectionQuarterly Report7 Nov 2025via asx_announcements
- Quarterly Activities Report and Appendix 4CQuarterly Report31 Oct 2025via asx_announcements
- Appendix 4E and 2025 Annual ReportAnnual Results29 Aug 2025via asx_announcements
- Quarterly Activities Report and Appendix 4CQuarterly Report31 Jul 2025via asx_announcements
- Quarterly Activities Report and Appendix 4CQuarterly Report30 Apr 2025via asx_announcements
- Appendix 4D and Half Year Report for period 31 Dec 2024Half Year Results27 Feb 2025via asx_announcements
Showing 10 of 23 reports